Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel Free FLNA Stock Alerts

Cassava Sciences (FLNA) Competitors

Cassava Sciences logo
$0.88 -0.02 (-1.72%)
As of 04:00 PM Eastern
Compare

FLNA vs. DERM, PLX, WHWK, MDWD, and VYGR

Should you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Journey Medical (DERM), Protalix BioTherapeutics (PLX), Whitehawk Therapeutics (WHWK), MediWound (MDWD), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.

How does Cassava Sciences compare to Journey Medical?

Cassava Sciences (NASDAQ:FLNA) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Journey Medical has higher revenue and earnings than Cassava Sciences. Journey Medical is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
Journey Medical$61.86M2.81-$11.43M-$0.37N/A

Cassava Sciences currently has a consensus target price of $5.00, suggesting a potential upside of 465.04%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 106.02%. Given Cassava Sciences' higher probable upside, research analysts clearly believe Cassava Sciences is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Journey Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. Journey Medical's average media sentiment score of 1.89 beat Cassava Sciences' score of 0.62 indicating that Journey Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Cassava Sciences Positive
Journey Medical Very Positive

Cassava Sciences has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Journey Medical -14.82%-35.57%-10.88%

38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Journey Medical beats Cassava Sciences on 10 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Protalix BioTherapeutics?

Cassava Sciences (NASDAQ:FLNA) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Protalix BioTherapeutics has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
Protalix BioTherapeutics$76.38M2.46$8.31M$0.1812.94

In the previous week, Cassava Sciences had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 1 mentions for Cassava Sciences and 0 mentions for Protalix BioTherapeutics. Cassava Sciences' average media sentiment score of 0.62 beat Protalix BioTherapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Cassava Sciences Positive
Protalix BioTherapeutics Neutral

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 465.04%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 415.02%. Given Cassava Sciences' higher possible upside, research analysts plainly believe Cassava Sciences is more favorable than Protalix BioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Protalix BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cassava Sciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Protalix BioTherapeutics -21.03%-30.89%-11.74%

Summary

Protalix BioTherapeutics beats Cassava Sciences on 7 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Whitehawk Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Cassava Sciences' return on equity of -53.90% beat Whitehawk Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Whitehawk Therapeutics N/A -79.63%-74.01%

38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Whitehawk Therapeutics has higher revenue and earnings than Cassava Sciences. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
Whitehawk Therapeutics$7.14M25.49-$20.60M-$1.68N/A

Cassava Sciences has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 465.04%. Whitehawk Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 122.83%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Whitehawk Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Whitehawk Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 1 mentions for Cassava Sciences. Whitehawk Therapeutics' average media sentiment score of 1.45 beat Cassava Sciences' score of 0.62 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cassava Sciences Positive
Whitehawk Therapeutics Positive

Summary

Whitehawk Therapeutics beats Cassava Sciences on 9 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to MediWound?

Cassava Sciences (NASDAQ:FLNA) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 465.04%. MediWound has a consensus price target of $34.00, suggesting a potential upside of 132.56%. Given Cassava Sciences' higher probable upside, equities research analysts clearly believe Cassava Sciences is more favorable than MediWound.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
MediWound
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

MediWound has higher revenue and earnings than Cassava Sciences. MediWound is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
MediWound$16.96M11.08-$23.88M-$2.26N/A

In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. MediWound's average media sentiment score of 1.87 beat Cassava Sciences' score of 0.62 indicating that MediWound is being referred to more favorably in the news media.

Company Overall Sentiment
Cassava Sciences Positive
MediWound Very Positive

Cassava Sciences has a beta of -0.73, meaning that its stock price is 173% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, meaning that its stock price is 86% less volatile than the broader market.

38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cassava Sciences has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Cassava Sciences' return on equity of -53.90% beat MediWound's return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
MediWound -180.30%-67.22%-31.87%

Summary

MediWound beats Cassava Sciences on 9 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Voyager Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Cassava Sciences has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Cassava Sciences' return on equity of -53.90% beat Voyager Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cassava SciencesN/A -53.90% -34.20%
Voyager Therapeutics -319.61%-55.97%-43.12%

Cassava Sciences has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A-$90.97M-$1.61N/A
Voyager Therapeutics$40.37M4.55-$119.72M-$1.97N/A

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 465.04%. Voyager Therapeutics has a consensus price target of $16.50, indicating a potential upside of 442.76%. Given Cassava Sciences' higher probable upside, equities research analysts clearly believe Cassava Sciences is more favorable than Voyager Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Voyager Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Voyager Therapeutics and 1 mentions for Cassava Sciences. Voyager Therapeutics' average media sentiment score of 0.94 beat Cassava Sciences' score of 0.62 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cassava Sciences Positive
Voyager Therapeutics Positive

Summary

Voyager Therapeutics beats Cassava Sciences on 9 of the 16 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for FLNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FLNA vs. The Competition

Export
MetricCassava SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$42.75M$3.09B$7.04B$12.13B
Dividend YieldN/A2.07%2.67%9.43%
P/E Ratio-0.5520.4727.3023.79
Price / SalesN/A394.03496.6976.37
Price / CashN/A26.6326.3946.66
Price / Book0.574.2910.276.10
Net Income-$90.97M$67.27M$3.60B$336.45M
7 Day Performance-12.39%-4.15%-1.79%-2.14%
1 Month Performance-26.26%-5.76%-2.66%-3.31%
1 Year Performance-62.82%10.47%18.22%13.49%

Cassava Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLNA
Cassava Sciences
1.8197 of 5 stars		$0.88
-1.7%		$5.00
+465.0%		-61.7%$42.75MN/AN/A20
DERM
Journey Medical
2.5477 of 5 stars		$7.11
-0.7%		$13.00
+82.8%		-16.1%$196.07M$61.86MN/A90
PLX
Protalix BioTherapeutics
2.2476 of 5 stars		$2.41
+1.1%		$12.00
+399.0%		+58.9%$193.78M$76.38MN/A200
WHWK
Whitehawk Therapeutics
2.373 of 5 stars		$3.83
-1.5%		$8.20
+114.1%		+89.7%$189.39M$7.14MN/A21
MDWD
MediWound
3.5141 of 5 stars		$14.69
+0.5%		$34.00
+131.4%		-28.9%$188.77M$16.96MN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 7/28/2026 by MarketBeat.com Staff.
From Our Partners
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
3 Signs of The Biggest “Melt-Up” in U.S. History
In 1995, a convergence of three economic triggers fueled the biggest market melt-up in U.S. history. One self-...
True Market Insiders | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Write This Down: A.R.M.
A secretive project tied to Elon Musk, nicknamed ARM, has caught investors' attention. Musk has suggested it c...
Paradigm Press | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
The $5 “Shadow SpaceX”
One mile from SpaceX's launchpad at Kennedy Space Center sits a tiny public company trading for less than 5 do...
Freedom Financial | Sponsoredtc pixel